skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

100+ Total results for product and free and sample content found

Citeline

Citeline Study Feasibility is launching soon!

Citeline Study Feasibility is launching soon!

Improve your clinical trial decisions and cycle times

Topic Clinical Trials

Scrip

Quick Listen: Scrip’s Five Must-Know Things

SC2008_FiveMustKnowThings_1200_Final

Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip's worldwide team, in this podcast version of Five Must-Know Things. 

Scrip

Scrip Asks…What Does 2021 Hold For Biopharma? Part 5: Business Environment And Strategy

SC2102_Scrip_Asks_Part5_Feature_image_1200

A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.

Scrip

Scancell Soars On 'Universal' COVID-19 Vaccine Claims

COVIDgears

The current coronavirus vaccines focus on the spike protein but the UK's Scancell believes it has a candidate that also targets the SARS-CoV-2 nucleocapsid protein which could help tackle existing and future variants.

Scrip

Regeneron And Lilly Are Back With Better COVID-19 Antibody Data – But Still Face Medical Skepticism

SCR2102_G1230425757_1250

After disappointing initially, Lilly and Regeneron are back with compelling data for their monoclonal antibody products, but still face challenges from new COVID-19 variants and medical skepticism.

Scrip

Lilly Oncology President Anne White On Loxo Success, What’s To Come

SC2102_LillyShade_1851003727_1200

White said the late 2019 creation of Loxo Oncology at Lilly to spearhead cancer R&D has exceeded her expectations. The executive also discussed COVID-19’s impact on drug sales and cancer screening. 

Scrip

Quick Listen: Scrip’s Five Must-Know Things

SC2008_FiveMustKnowThings_1200_Final

Join us for an audio catch-up on the latest key developments in the worldwide biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things. 

Scrip

Scrip's Q4 Earnings Preview Podcast: Where Does Pharma Stand?

4thQuarterComputerKey_jurgenfr_156694661_1200x675

Joined by Datamonitor Healthcare analyst Derek Burkhard, Scrip editors discuss the pharma landscape coming out of 2020 and where industry stands heading into 2021. 

Pink Sheet

UK Explains New Reliance Routes To Approval Based On EU Dossiers

UK Explains New ‘Reliance’ Routes To Approval Based On EU Dossiers

Companies seeking marketing authorizations in the UK or Great Britain will be able to make use of two new “reliance” procedures offering regulatory assessment times of 67 days or less if their products have already gone through the EU centralized or decentralized approval systems.

Topic Brexit Pharma-Brexit

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: